Pharmacy advocacy group urges 340B oversight shift to CMS

ADAP Advocacy is pushing for the 340B Drug Pricing Program's oversight to switch from the Health Resources and Services Administration (HRSA) to the Centers for Medicare & Medicaid Services (CMS), citing longstanding issues with regulatory enforcement. They argue this change would better ensure compliance and oversight, which is crucial as the 340B program aims to keep drug costs low for eligible patients. This move could have significant implications for how drug pricing and distribution are managed in healthcare, potentially leading to more effective oversight and better outcomes for patients relying on the program.